Yarrow Bioscience Inc
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $570.0K | $501.0K | $424.0K | $477.0K | $931.0K | $21.0M | $0 | $0 |
| Cost of Revenue | — | — | — | — | $3.3M | $1.4M | $0 | $0 |
| Gross Profit | — | — | — | — | $-2.4M | $19.6M | $0 | $0 |
| Gross Margin | — | — | — | — | -259.6% | 93.4% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $19.2M | $30.9M | $16.3M | $18.4M | $19.5M | $43.5M | $51.2M | $64.5M |
| SG&A Expense | $11.1M | $13.2M | $13.4M | $16.4M | $20.3M | $89.5M | $45.1M | $14.0M |
| Operating Income | $-29.7M | $-43.6M | $-29.3M | $-34.3M | $-38.9M | $-252.5M | $-95.9M | $-74.9M |
| Operating Margin | -5,219.1% | -8,710.0% | -6,900.5% | -7,189.7% | -4,179.5% | -1,203.0% | — | — |
| Interest Expense | — | — | — | $0 | $5.6M | $4.4M | $921.0K | $0 |
| Pretax Income | $-26.7M | $-39.8M | $-27.9M | $-33.9M | $-44.7M | $-255.8M | $-95.4M | $-74.0M |
| Income Tax Expense | $4.0K | $4.0K | $0 | $13.0K | $-448.0K | $-258.0K | $-176.0K | $212.0K |
| Net Income | $-26.5M | $-39.8M | $-28.5M | $-23.2M | $-73.3M | $-255.6M | $-95.2M | $-74.2M |
| Net Margin | -4,646.1% | -7,950.9% | -6,710.4% | -4,865.8% | -7,876.4% | -1,217.4% | — | — |
| EPS (Basic) | $-0.62 | $-0.93 | $-0.70 | $-0.61 | $-2.14 | $0.66 | $0.94 | $0.96 |
| EPS (Diluted) | $-0.62 | $-0.93 | $-0.70 | $-0.61 | $-2.14 | $0.66 | $0.94 | $0.96 |
| Shares Outstanding (Basic) | 42.8M | 42.6M | 41.1M | 38.2M | 34.3M | 389.0M | 109.4M | 278.8M |
| Shares Outstanding (Diluted) | 42.8M | 42.6M | 41.1M | 38.2M | 34.3M | 389.0M | 109.4M | 278.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |